ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease

Rainer Kuefer, Kathleen C. Day, Celina G. Kleer, Michael S. Sabel, Matthias D. Hofer, Sooryanarayana Varambally, Christoph S. Zorn, Arul M. Chinnaiyan, Mark A. Rubin, Mark L. Day*

*Corresponding author for this work

Research output: Contribution to journalArticle

71 Scopus citations

Abstract

The aim of the current study was to evaluate the expression of ADAM15 disintegrin (ADAM15) in a broad spectrum of human tumors. The transcript for ADAM15 was found to be highly upregulated in a variety of tumor cDNA expression arrays. ADAM15 protein expression was examined in tissue microarrays (TMAs) consisting of 638 tissue cores. TMA analysis revealed that ADAM15 protein was significantly increased in multiple types of adenocarcinoma, specifically in prostate and breast cancer specimens. Statistical association was observed with disease progression within clinical parameters of predictive outcome for both prostate and breast cancers, pertaining to Gleason sum and angioinvasion, respectively. In this report, we also present data from a cDNA microarray of prostate cancer (PCa), where we compared transfected LNCaP cells that overexpress ADAM15 to vector control cells. In these experiments, we found that ADAM15 expression was associated with the induction of specific proteases and protease inhibitors, particularly tissue inhibitor of metalloproteinase 2, as validated in a separate PCa TMA. These results suggest that ADAM15 is generally overexpressed in adenocarcinoma and is highly associated with metastatic progression of prostate and breast cancers.

Original languageEnglish (US)
Pages (from-to)319-329
Number of pages11
JournalNeoplasia
Volume8
Issue number4
DOIs
StatePublished - Jan 1 2006

Keywords

  • ADAM15 disintegrin
  • Breast cancer
  • Prostate cancer
  • Tissue microarray
  • cDNA microarray

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease'. Together they form a unique fingerprint.

  • Cite this

    Kuefer, R., Day, K. C., Kleer, C. G., Sabel, M. S., Hofer, M. D., Varambally, S., Zorn, C. S., Chinnaiyan, A. M., Rubin, M. A., & Day, M. L. (2006). ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. Neoplasia, 8(4), 319-329. https://doi.org/10.1593/neo.05682